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Abstract Azithromycin accumulates in lysosomes where it 
causes phospholipidosis. In homogenates prepared by sonication 
of fibroblasts incubated for 3 days with azithromycin (66 pM), 
the activities of sulfatase A, phospholipase AI, N-acetyl-~- 
hexosaminidase and cathepsin B increased from 180 to 330%, 
but not those of 3 non-lysosomal enzymes. The level of cathepsin 
B mRNA was unaffected. The hyperactivity induced by 
azithromycin is non-reversible upon drug withdrawal, prevented 
by coincubation with cycloheximide, affects the Vmax but not the 
Am, and is not reproduced with gentamicin, another drug also 
causing lysosomal phospholipidosis. The data therefore suggest 
that azithromycin increases the level of lysosomal enzymes by a 
mechanism distinct from the stimulation of gene expression but 
requiring protein synthesis, and is not in direct relation to the 
lysosomal phospholipidosis. 
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1. Introduction 
Azithromycin is a dicationic derivative of erythromycin A 
[1,2] which avidly accumulates in tissues [3,4] and in cultured 
mammalian cells, reaching intracellular to extracellular con- 
centrations ratios of 100 and more [5]. Cell fractionation stud- 
ies show that the bulk of the drug accumulated by cells lo- 
calizes in the lysosomes [6]. Azithromycin induces a 
thesaurismosis characterized morphologically by conspicuous 
enlargement of the lysosomes which display the prominent 
deposition of pseudomyelinic structures, and, biochemically, 
by a marked increase of the lysosomal content in undegraded 
phospholipids [7,8]. In vitro, azithromycin is a potent inhib- 
itor of the activity of lysosomal phospholipase A1 (measured 
towards phosphatidytcholine cluded in negatively charged 
liposomes), presumably because the drug binds to the phos- 
pholipid bilayers preventing the enzyme from exerting fully its 
activity [9]. Somewhat paradoxically, however, we observed 
and report here that the activity of phospholipase A1 is actu- 
ally increased when assayed in the presence of detergents in
lysates of fibroblasts preincubated with azithromycin. To in- 
vestigate the specificity and significance of this effect, we have 
examined the influence of azithromycin on the activity of 
other lysosomal and non-lysosomal enzymes, and have com- 
pared azithromycin to another lysosomotropic antibiotic, gen- 
tamicin, which also induces a lysosomal phospholipidosis [10]. 
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2. Material and methods 
2.1. Cell culture 
Embryonic fibroblasts from Wistar rats were cultivated and col- 
lected essentially as described earlier [11]. Cell proteins and phospho- 
lipids were assayed using standard techniques [12-14]. 
2.2. Drugs 
Azithromycin was a gift from Pfizer (Pfizer Central Research, Gro- 
ton, CT) and gentamicin from Schering-Plough Corp. (Kenilworth, 
N J). These drugs were assayed by a disc-plate microbiological assay 
using Bacillus subtilis as test organism [15], as described earlier [16]. 
2.3. Enzyme assays 
Lysosomal enzymes were assayed in the presence ofdetergent with 
the following substrates (obtained from Sigma Chemical Co. (St 
Louis, MO) or from Amersham (Amersham International p c, Bucks, 
UK)): cathepsin B (EC 3.4.22.1), 2-N-benzoyl-DL-arginine-2-naphthyl- 
amide [17]; N-acetyl-~-hexosaminidase (EC 3.2.1.30), p-nitrophenyl 2-
acetamido-13-D-glucopyranoside [18]; arylsulfatase A (EC 3.1.6.1), p- 
nitrocatecholsulfate [19]; and phospholipase A1 (EC 3.1.1.32), L-3- 
phosphatidylcholine, 1-palmitoyl-2-[1-14C]oleoyl [20]. The plasma 
membrane enzyme 5'-nucleotidase (EC 3.1.3.5) was assayed with ade- 
nosine 5'-monophosphoric acid disodium salt [21]. Two cytosolic en- 
zymes were also assayed, namely lactate dehydrogenase (EC 1.1.1.8), 
with pyruvic acid and nicotinamide adenine dinucleotide disodium 
salt (reduced form) [22], and phosphoglucomutase (EC 5.4.2.2), with 
glucose l-phosphate [23]. 
2.4. Northern blot analysis 
Poly(A) + RNA, prepared using the Micro-Fast Track mRNA iso- 
lation system (Invitrogen, San Diego, CA), was electrophoresed on 
1.3% agarose-formaldehyde gel, transferred onto nitrocellulose paper 
(Schleicher and Schuell, Millipore, Brussels, Belgium), hybridized with 
:~2p-labeled probes and autoradiographed. The cathepsin B probe was 
obtained by polymerase chain reaction (PCR) amplification ofa frag- 
ment of 481 bp (nucleotides 360 841) of the gene encoding rat ca- 
thepsin B inserted in prcB5 (a plasmid kindly offered by Dr. Donald 
Steiner, University of Chicago, Illinois) with oligonucleotides CGIS 
(5'ACACCATGTCAATGGCTCCCG3', nucleotides 360-380) and 
CG2AS (5'GACTATACAATCAAGTCCCAGC3', nucleotides 820- 
841). Control hybridization was performed on the same membrane 
with a rat actin probe obtained by reverse transcription (RT)-PCR 
amplification of rat embryo fibroblasts poly(A) + RNA. The primers 
used were 5'AAGAGAGGTATCCTGACCCTG3' (exon 2) and 
5'CCATCTCCTGCTCGAAGTCTA3' (exon 3). The two PCR reac- 
tions were carried out using the Dynazyme (Finnzymes Oy, Espoo, 
Finland) and the PCR products were 32p-labeled byrandom priming 
using the Megaprime DNA labelling system (Amersharn I ternational 
plc, Bucks, UK) before hybridization. 
3. Results 
Table 1 shows that a 3 day incubation with azithromycin 
(66.6 p.M; 50 mg/1) induced a marked increase in the total cell 
phospholipids, together with an increased activity of all 4 
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lysosomal enzymes assayed. In contrast, no change of activity 
was seen for two cytosolic enzymes, and a slight decrease in 
activity was noted for the plasma membrane-linked nzyme 
5'-nucleotidase. Table 1 also shows that gentamicin, at a com- 
parable cellular concentration, caused a phospholipidosis a  
marked as that of azithromycin, but no biologically significant 
change in the activities of two lysosomal enzymes and a de- 
crease for the two others, especially phospholipase A1. 
Because cathepsin B showed the greatest increase in activity 
after incubation of the cells with azithromycin, all further 
studies were focused on this enzyme. We first checked that 
azithromycin did not increase the activity of cathepsin B when 
added directly to the incubation mixture. We actually noted a 
slight decrease in activity (~-10%) of the largest achievable 
concentration (0.67 mM), without evidence of apparent 
change in K,r,. In parallel, we also determined the kinetic 
parameters of N-acetyl-~3-hexosaminidase n lysates of azithro- 
mycin-treated cells and found no significant change in K~n 
(~0.4 mM) but a definitively increased Vm~. In a second 
step, we examined the time dependence of the effect of azi- 
thromycin on cathepsin B activity and its reversibility, in re- 
lation to the drug intake and efflux on the one hand, and the 
development of the phospholipidosis, on the other. Fig. 1 
shows that whereas the drug accumulated very quickly (reach- 
ing its maximal cellular level after only 1 day), the change in 
cathepsin B activity occurred only after 2 days, somewhat but 
not strictly in relation with the accumulation of phospholip° 
ids. Both the drug accumulation and the phospholipid over- 
loading recessed after azithromycin withdrawal. In contrast, 
the activity of cathepsin B remained elevated and even in- 
creased still more during the washout period. 
Cycloheximide, an inhibitor of protein synthesis in eucar- 
yotic cells [24], completely abolished the effect of azithromycin 
on cathepsin B activity. Thus, as previously described [25], 
cycloheximide alone decreased the activity of cathepsin B to 
20% of the control values. Co-incubation with azithromy- 
cin did not affect this decrease. 
We then directly evaluated by Northern blot analysis the 
amounts of cathepsin B mRNA present in fibroblasts after 
incubation with azithromycin. The Northern blot, prepared 
with poly(A) + RNA from fibroblasts incubated for 2 days 
with azithromycin (50 mg/l; 66.6 gM) or from control cells, 
was hybridized with a rat cathepsin B probe covering nucleo- 
tides 360-841. A unique band of approx. 2.2 kb was observed 
(Fig. 2), the intensity of which was similar for control and 
treated cells. Control hybridization of the same preparation 
with a rat actin probe revealed a similar amount of hybridiz- 
able actin mRNA (band at 2.1 kb) under the two tested con- 
ditions. 
4. Discussion 
As demonstrated here, azithromycin causes conspicuous 
phospholipidosis in cultured cells. Other studies from our la- 
boratory have shown that this phospholipidosis affects pri- 
marily the lysosomes [8] and can reasonably be ascribed (a) 
to the capacity of this antibiotic to accumulate in large 
amounts in these organelles [6] and (b) to its ability to bind 
to phospholipid bilayers and thereby to inhibit the activity of 
lysosomal phospholipase A1 (and probably other phospholip- 
ases), as demonstrated by in vitro studies [9]. 
Paradoxically, however, we observe here that the incubation 
of fibroblasts with azithromycin i creases the activity of lyso- 
somal phospholipase A1 that can be recovered from the cell 
lysates. The drug also increases the activity of other lysosomal 
hydrolases, i.e. a series of enzymes probably not involved in 
the development of the phospholipidosis, and most notably 
cathepsin B. Moreover, gentamicin, which also induces lyso- 
somal phospholipidosis [10], does not cause an increase in 
lysosomal enzyme activities but rather a decrease in the activ- 
ity of phospholipase A1. 
Since azithromycin causes no increase in the activities of 
non-lysosomal enzymes, it is probably safe to assume that 
we are not dealing here with an unspecific stimulation of 
protein synthesis. The experiments with cycloheximide never- 
theless demonstrate that protein synthesis, or a process di- 
rectly dependent on protein synthesis, must be operative for 
azithromycin to exert its stimulatory effect. Yet, the Northern 
blot experiments also indicate that the concentration of 
mRNA of cathepsin B is unchanged in spite of its increased 
activity, ruling out a direct or indirect effect of azithromycin 
on gene expression. 
The slow onset in the change of activity of cathepsin B, 
compared to the rate of intracellular accumulation of azithro- 
mycin, and its lack of reversibility in spite of the efflux of the 
drug show that the hyperactivity caused by azithromycin is 
not merely and solely dependent upon the presence of drug in 
lysosomes or somewhere lse in cells in close contact with the 
Table 1 
Activity of lysosomal (upper panel) or non-lysosomal (lower panel) enzymes in cell homogenates 
Azithromycin (50 mg/1, 3 days) Gentamicin (1 mg/ml, 5 days) 
Drug cellular concentration 
Total cellular phospholipids 
22.2 _+ 0.5 ~ 25.9 + 2.5 
159.0 + 5.0 b'a 145.9 + 0.2 d 
Lysosomal 
Cathepsin B 329.5 + 11.8 b'c 131.1 _. 20.7 Ns 
N-AcetyH3-hexosaminidase 204.4 + 10.7': 118.1 + 4.9 a 
Sulfatase A 182.5 + 1.4 c 79.7 + 2.0 a 
Phospholipase Ai 190.2 + 11.9 ~' 40.9 + 1.3 c 
Non-lysosomal 
Lactate dehydrogenase 97.7 + 5.5 Ns ND 
Phosphoglucomutase 102.0 + 7.5 Ns ND 
5'-Nucleotidase 70.4 + 12.0 e ND 
qn gg/mg protein, corresponding to 5.7 and 11.2 mM, respectively. 
bin % of control values (mean + S.D. of 3 independent experiments). 
Cp < 0.001 ; d0.001 < p < 0.01 ; e0.01 < p < 0.05; NS, not significantly different from controls; N D, not determined. 
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enzyme. A direct effect of the drug on the enzymes also seems 
unlikely in view of the in vitro data which show that: (a) 
azithromycin does not significantly alter the kinetic properties 
of cathepsin B; (b) azithromycin is without effect on phos- 
pholipase A1 when this enzyme is assayed in vitro on deter- 
gent-dispersed phospholipid micelles [8]; and (c) azithromycin 
is actually a potent inhibitor of phospholipase A1 when the 
activity is assayed towards a substrate included in organized 
membrane bilayers [9]. 
Finally, the effect of cycloheximide on azithromycin-in- 
duced hyperactivity of cathepsin B is opposite to what we 
described earlier for leupeptin, an inhibitor of cysteine 
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Fig. 1. Time evolution of the cellular to extracellular drug concen- 
tration ratio (Cc/Ce; open symbols; upper panel; this ratio was de- 
termined as described in [6]), the content of total cellular phospholi- 
pids (PL; closed symbols; upper panel) and the activity of cathepsin 
B (lower panel) in homogenates of rat fibroblasts incubated for 3 
days with azithromycin (50 mg/l; 66.6/aM) (A), and during a subse- 
quent reincubation in drug-free medium (B). Phospholipid content 
and enzyme activity are expressed in % of control values. Data in 
(A,B) were obtained from 2 independent experiments, explaining the 
differences between the values recorded at day 3 in (A) and noted 
for day 0 in (B). Results are given as mean + S.D. (n = 3). 
Act in 
Fig. 2. Northern blot analysis of total mRNA of rat embryo fibro- 
blasts incubated for 2 days in the absence (CTL) or presence of azi- 
thromycin (Az; 50 rag/l). Lanes contained 2 Bg of poly(A) + RNA. 
The membrane was hybridized with a probe covering nucleotides 
360-841 of the cathepsin B coding sequence (upper panel). Control 
hybridization was performed on the same membrane with a rat ac- 
tin probe (lower panel). 
proteinases. The latter also causes an increase of lysosomal 
enzyme activities in cells cultivated in its presence but by im- 
pairing their breakdown [25], and its effect is therefore not 
antagonized by cycloheximide. This difference of behavior 
therefore suggests that azithromycin exerts its effect not in 
the lysosomes but probably at some step during the processing 
and packaging of the lysosomal enzymes, which is protein 
synthesis-dependent. Because azithromycin probably accumu- 
lates in cells by proton-trapping (its accumulation is abolished 
if cells are co-incubated with the proton ionophore monensin, 
[8]), it is tempting to speculate that the drug will partly reach 
the Golgi vesicles and/or the so-called 'acidified-prelysosomal 
compartment' hrough which lysosomal enzymes are chan- 
nelled to lysosomes [26]. In contrast, gentamicin, which is a 
very polar drug (see structural formula and biophysical prop- 
erties in [27]), enters by endocytosis, and probably has only 
very limited access, if any, to that compartment. 
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